Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2003
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207885 Nitrogen compounds such as 6-chloro-3-ethyl-2-(2-thiazol-2-yl -imidazol-1-ylmethyl)-imidazo(1,2-b)pyridazine used for prophylaxis of nervous system disorders
11/06/2003US20030207883 Indazole benzimidazole compounds
11/06/2003US20030207882 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207875 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207863 Preventives and remedies for central nervous system diseases
11/06/2003US20030207860 Neuropeptide Y Y5 receptor antagonists
11/06/2003US20030207858 Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function.
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207847 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207807 A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and a protein
11/06/2003US20030207434 Phosphodiesterases
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207347 Useful in treating ovarian, renal, neurological, cardiovascular disorders and modulating angiogenesis, cell proliferation
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207293 Cryptic-like secreted protein
11/06/2003US20030207263 Method of screening therapeutic agents
11/06/2003US20030206975 Compositions and methods of use for extracts of magnoliaceae plants
11/06/2003US20030206941 Fast dissolving orally consumable films
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206869 Delivery of antidepressants through an inhalation route
11/06/2003US20030206867 Spray that delivers unit doses that are highly accurate as to the volume discharged and which leave no significant quantity of the composition in the delivery means.
11/06/2003CA2496454A1 Transdermal analgesic systems with reduced abuse potential
11/06/2003CA2484223A1 Use of human neural stem cells secreting gdnf for treatment of parkinson's and other neurodegenerative diseases
11/06/2003CA2484217A1 Muscarinic antagonists
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483980A1 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
11/06/2003CA2483729A1 Method for treating anxiety and mood disorders in older subjects
11/06/2003CA2483636A1 3,4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
11/06/2003CA2483525A1 Method of measuring neprilysin activity
11/06/2003CA2483505A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483431A1 Alternatively spliced nucleic acid molecules
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483270A1 Treatment of alpha-galactosidase a deficiency
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483203A1 Hyperforin halogenated derivatives, the use thereof and formulations containing them
11/06/2003CA2483093A1 Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2483072A1 Cannabinoids
11/06/2003CA2482455A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003CA2481324A1 [1,4]diazocino [7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480293A1 New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2478680A1 Chimeric hybrid analgesics
11/06/2003CA2454612A1 Ultrasonic doppler effect speed measurement
11/05/2003EP1359159A2 Analogues of GLP-1
11/05/2003EP1359152A2 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
11/05/2003EP1359146A2 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
11/05/2003EP1358883A1 Re-epithelializing pharmaceutical compositions containing xanthan gum
11/05/2003EP1358336A2 Human serine-threonine kinase
11/05/2003EP1358330A2 Transporters and ion channels
11/05/2003EP1358329A2 Lipid-associated molecules
11/05/2003EP1358328A2 Regulation of human serotonin-like g protein-coupled recepter
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358325A2 Protein modification and maintenance molecules
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358320A2 68730 and 69112 protein kinase molecules and uses therefor
11/05/2003EP1358316A1 Enteric nervous system derived stem and progenitor cells and uses thereof
11/05/2003EP1358213A2 Humanized antibodies that recognize beta amyloid peptide
11/05/2003EP1358209A2 Crystallization of igf-1
11/05/2003EP1358204A1 Tripeptide derivatives for the treatment of neurodegenerative diseases
11/05/2003EP1358186A1 Laulimalide derivatives
11/05/2003EP1358182A1 Diazocine derivatives and their use as tryptase inhibitors
11/05/2003EP1358178A2 Sulfonamide lactam inhibitors of factor xa
11/05/2003EP1358177A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
11/05/2003EP1358171A2 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
11/05/2003EP1358165A1 Imidazole derivatives
11/05/2003EP1358161A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
11/05/2003EP1358160A1 Aminal diones as potassium channel openers
11/05/2003EP1358157A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands
11/05/2003EP1358155A1 Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as mmp inhibitors
11/05/2003EP1358153A1 Ophthalmic compositions for treating ocular hypertension
11/05/2003EP1358150A1 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
11/05/2003EP1357941A2 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
11/05/2003EP1357935A2 Method of reducing side effects of chemotherapy in cancer patients
11/05/2003EP1357929A2 Modulation of immune response and methods based thereon
11/05/2003EP1357923A1 Herbal composition for-the prevention and treatment of dementia
11/05/2003EP1357915A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/05/2003EP1357913A1 Heterocyclic inhibitors of glycine transporter 2
11/05/2003EP1357909A1 Il-8 receptor antagonists
11/05/2003EP1357908A2 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
11/05/2003EP1357906A2 Blockade of sodium channels by phenol derivatives
11/05/2003EP1357903A2 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO b]THIOPHENE AND SALTS THEREOF
11/05/2003EP1357900A2 Process for production of nanoparticles and microparticles by spray freezing into liquid
11/05/2003EP1357898A2 Improved controlled release oral dosage form
11/05/2003EP1357855A2 Ophthalmic compositions for treating ocular hypertension
11/05/2003EP1268480B1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
11/05/2003EP1220858B1 Oxazinoquinolones useful for the treatment of viral infections
11/05/2003EP1176961B1 Nicotine delivery systems
1 ... 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 ... 1833